About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Cancer Research UK Offers New Hope To Cancer Patients

by Medindia Content Team on May 5, 2006 at 2:36 PM
Font : A-A+

Cancer Research UK Offers New Hope To Cancer Patients

In a new clinical development partnership being launched by the Cancer Research UK, and its commercial arm, Cancer Research Technology (CRT) plans to take up drug candidates that pharmaceuticals companies have 'deprioritised' for not showing enough commercial promise following their preclinical studies. By this they plan to develop new treatments from anti-cancer drugs that have been shelved by pharmaceutical and biotechnology companies.

Under the scheme, companies will hand over molecules that once showed promise, but were never developed, and CRT will take on the clinical trials for those molecules. It is proposed that the Pharma and biotech firms will keep the intellectual property rights to the molecules they had shelved. After CRT has done clinical trials, the company will be given the option to take the molecule back and develop it themselves, or to leave it in the hands of the CRT scientists.

Advertisement

Harpal Kumar CRT chief executive hopes that the scheme that would cost up to Ģ2 million a year, will help to identify at least five more drug molecules annually, to add to CRT's current portfolio of around 25 licensed molecules in the clinic.Kumar sounding very optimistic said that they Hopefully would be flooded with opportunities, he told reporters. Kumar was also keen to state a point that the project was not being developed as a money-spinner for the charity, but he said that the Cancer Research UK does expects to receive a share of any financial return made by the companies.

Richard Tiner, medical director of the Association of the British Pharmaceutical Industry (ABPI) said that he personally could saw no reason for the scheme to fail, but accepted that there could be legal hurdles surrounding intellectual property rights and contracts. He explained that inevitably when discussing business or IP issues there will be differences of opinion. The CRT has approached around 20 leading pharmaceutical and biotech companies, and is close to deals with three. Victoria John, head of licensing for the clinical development partnerships scheme, said that those three opportunities is very good at this stage.
Advertisement

Kumar explained that the nature of the scheme means that many of the drug candidates might be used for rare cancers, but this will not colour the decision about which drugs to develop. He explained that just because one type of cancer is common, it doesn't mean it would get a higher priority than a rarer cancer.

ABPI's Tiner predicts that other medical charities will be watching the process carefully.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Sugar Intake and Oral Health
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Cancer Facts Cancer Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Most Popular on Medindia

Color Blindness Calculator Hearing Loss Calculator Iron Intake Calculator Pregnancy Confirmation Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Loram (2 mg) (Lorazepam) Find a Doctor Sanatogen Drug Interaction Checker Nutam (400mg) (Piracetam)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE

×

Cancer Research UK Offers New Hope To Cancer Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests